Summary of Study ST002063
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001306. The data can be accessed directly via it's Project DOI: 10.21228/M8WT4R This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST002063 |
| Study Title | Intravenous lipopolysaccharide infusion and the bovine metabolome |
| Study Type | MS plasma lipidomics and metabolomics |
| Study Summary | The effects of lipopolysaccharides (i.e., endotoxin; LPS) on metabolism are poorly defined in lactating dairy cattle experiencing hyperlipidemia. Our objective was to explore the effects of acute intravenous LPS administration on metabolism in late-lactation Holstein cows experiencing hyperlipidemia. Ten non-pregnant lactating Holstein cows (273 ± 35 d in milk) were administered a single bolus of saline (3 mL of saline; n = 5) or LPS (0.375 μg of LPS/kg of body weight; n = 5). Simultaneously, cows were intravenously infused a triglyceride emulsion and fasted for 16 h to induce hyperlipidemia in an attempt to model the periparturient period. Blood was sampled at routine intervals. Changes in circulating total fatty acid concentrations and inflammatory parameters were measured. Plasma samples were analyzed using untargeted lipidomics and metabolomics. Endotoxin increased circulating serum amyloid A, LPS-binding protein, and cortisol concentrations. Endotoxin administration decreased plasma lysophosphatidylcholine (LPC) concentrations and increased select plasma ceramide concentrations. These outcomes suggest modulation of the immune response and insulin action. Lipopolysaccharide decreased the ratio of phosphatidylcholine to phosphatidylethanomanine, which potentially indicate a decrease in the hepatic activation of phosphatidylethanolamine N-methyltransferase and triglyceride export. Endotoxin administration also increased plasma concentrations of pyruvic and lactic acids, and decreased plasma citric acid concentrations, which implicate the upregulation of glycolysis and downregulation of the citric acid cycle (i.e., the Warburg effect), potentially in leukocytes. Acute intravenous LPS administration decreased circulating LPC concentrations, modified ceramide and glycerophospholipid concentrations, and influenced intermediary metabolism in dairy cows experiencing hyperlipidemia. |
| Institute | Cornell University |
| Department | Animal Science |
| Laboratory | McFadden lab |
| Last Name | Javaid |
| First Name | Awais |
| Address | 400 Warren Rd, Ithaca, New York, 14850, USA |
| aj366@cornell.edu | |
| Phone | 6072287246 |
| Submit Date | 2022-01-09 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzXML |
| Analysis Type Detail | LC-MS |
| Release Date | 2022-06-30 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001306 |
| Project DOI: | doi: 10.21228/M8WT4R |
| Project Title: | Intravenous lipopolysaccharide infusion and the bovine metabolome |
| Project Type: | MS lipidomics and metabolomics |
| Project Summary: | The effects of lipopolysaccharides (i.e., endotoxin; LPS) on metabolism are poorly defined in lactating dairy cattle experiencing hyperlipidemia. Our objective was to explore the effects of acute intravenous LPS administration on metabolism in late-lactation Holstein cows experiencing hyperlipidemia. Ten non-pregnant lactating Holstein cows (273 ± 35 d in milk) were administered a single bolus of saline (3 mL of saline; n = 5) or LPS (0.375 μg of LPS/kg of body weight; n = 5). Simultaneously, cows were intravenously infused a triglyceride emulsion and fasted for 16 h to induce hyperlipidemia in an attempt to model the periparturient period. Blood was sampled at routine intervals. Changes in circulating total fatty acid concentrations and inflammatory parameters were measured. Plasma samples were analyzed using untargeted lipidomics and metabolomics. Endotoxin increased circulating serum amyloid A, LPS-binding protein, and cortisol concentrations. Endotoxin administration decreased plasma lysophosphatidylcholine (LPC) concentrations and increased select plasma ceramide concentrations. These outcomes suggest modulation of the immune response and insulin action. Lipopolysaccharide decreased the ratio of phosphatidylcholine to phosphatidylethanomanine, which potentially indicate a decrease in the hepatic activation of phosphatidylethanolamine N-methyltransferase and triglyceride export. Endotoxin administration also increased plasma concentrations of pyruvic and lactic acids, and decreased plasma citric acid concentrations, which implicate the upregulation of glycolysis and downregulation of the citric acid cycle (i.e., the Warburg effect), potentially in leukocytes. Acute intravenous LPS administration decreased circulating LPC concentrations, modified ceramide and glycerophospholipid concentrations, and influenced intermediary metabolism in dairy cows experiencing hyperlipidemia. |
| Institute: | Animal Science |
| Department: | Animal Science |
| Laboratory: | McFadden lab |
| Last Name: | Javaid |
| First Name: | Awais |
| Address: | 400 Warren Rd, Ithaca, New York, 14850, USA |
| Email: | aj366@cornell.edu |
| Phone: | 6072287246 |
| Funding Source: | Agriculture and Food Research Initiative grant no. 2018-67015-27548 |
Subject:
| Subject ID: | SU002145 |
| Subject Type: | Mammal |
| Subject Species: | Bos taurus |
| Taxonomy ID: | 9913 |
| Genotype Strain: | Holstein dairy cows |
| Age Or Age Range: | 4- 5 years |
| Weight Or Weight Range: | 733-797 |
| Gender: | Female |
| Animal Housing: | Tie stall |
| Animal Feed: | TMR Ad lib |
| Animal Water: | Ad libitum |
| Animal Inclusion Criteria: | lactation stage, Days in milk |
Factors:
Subject type: Mammal; Subject species: Bos taurus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Time |
|---|---|---|
| SA194101 | 233-10336_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194102 | 234-9855_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194103 | 231-9852_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194104 | 230-9609_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194105 | 232-9610_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194106 | 238-9785_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194107 | 237-10008_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194108 | 235-10218_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194109 | 239-10103_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194110 | 236-8473_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194111 | 241-9852_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194112 | 240-9609_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194113 | 244-9855_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194114 | 242-9610_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194115 | 243-10336_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194116 | 9609CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194117 | 9852CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194118 | 9855CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194119 | 10336CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194120 | 9610CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194121 | 249-10103_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194122 | 245-10218_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194123 | 246-8473_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194124 | 248-9785_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194125 | 247-10008_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194126 | 10218LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194127 | 10103LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194128 | 8473LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194129 | 9785LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194130 | 10008LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194131 | 251-9852_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194132 | 254-9855_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194133 | 250-9609_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194134 | 253-10336_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194135 | 252-9610_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194136 | 257-10008_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194137 | 259-10103_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194138 | 255-10218_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194139 | 258-9785_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194140 | 256-8473_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194141 | 264-9855_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194142 | 260-9609_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194143 | 262-9610_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194144 | 261-9852_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194145 | 263-10336_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194146 | 265-10218_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194147 | 266-8473_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194148 | 267-10008_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194149 | 269-10103_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194150 | 268-9785_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194151 | 211-9852_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194152 | 210-9609_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194153 | 214-9855_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194154 | 213-10336_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194155 | 212-9610_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194156 | 216-8473_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194157 | 218-9785_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194158 | 217-10008_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194159 | 215-10218_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194160 | 219-10103_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194161 | 222-9610_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194162 | 220-9609_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194163 | 224-9855_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194164 | 223-10336_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194165 | 221-9852_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194166 | 9855CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194167 | 10336CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194168 | 9852CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194169 | 9609CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194170 | 9610CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194171 | 227-10008_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194172 | 229-10103_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194173 | 228-9785_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194174 | 226-8473_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194175 | 225-10218_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194176 | 8473LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194177 | 9785LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194178 | 10103LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194179 | 10008LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194180 | 10218LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194098 | QC_3_NEG.raw | . | Treatment:. | Category:Metabolomics |
| SA194099 | QC_1_NEG.raw | . | Treatment:. | Category:Metabolomics |
| SA194100 | QC_2_NEG.raw | . | Treatment:. | Category:Metabolomics |
| SA194078 | 202-9610_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194079 | 204-9855_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194080 | 200-9609_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194081 | 201-9852_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194082 | 203-10336_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194083 | 10336CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194084 | 9610CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194085 | 9852CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194086 | 9855CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194087 | 9609CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194088 | 206-8473_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194089 | 209-10103_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194090 | 208-9785_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194091 | 205-10218_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194092 | 207-10008_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194093 | 10008LPS-IL-0_NEG.raw | - | Treatment:LPS | Category:Metabolomics |
| SA194094 | 8473LPS-IL-0_NEG.raw | - | Treatment:LPS | Category:Metabolomics |
Collection:
| Collection ID: | CO002138 |
| Collection Summary: | Blood was collected via coccygeal venipuncture after the morning milking during the baseline period and at -0.5, 0, 4, 8, 16, 24, and 48 h, relative to saline or LPS administration. Plasma samples were incubated on ice for 30 min before centrifugation. |
| Collection Protocol ID: | N/A |
| Collection Protocol Filename: | Collection_Protocol.docx |
| Collection Protocol Comments: | N/A |
| Sample Type: | Blood (plasma) |
| Collection Method: | Blood collection using venipuncture needle |
| Collection Location: | Coccygeal venipuncture |
| Collection Frequency: | At interval of -0.5, 0, 4, 8, 16, 24, and 48 h respectively |
| Collection Duration: | 1 min |
| Volumeoramount Collected: | 10ml |
| Storage Conditions: | -20℃ |
| Collection Vials: | 10 ml blood vial |
| Storage Vials: | Eppendorf tubes 2ml |
| Collection Tube Temp: | 4°C |
Treatment:
| Treatment ID: | TR002157 |
| Treatment Summary: | Sterile saline (CON; n = 5) or 2) LPS (0.375 μg of LPS/kg of BW in sterile saline; Escherichia coli O55:B5; Sigma Aldrich, St. Louis, MO; n = 5) |
| Treatment Protocol ID: | N/A |
| Treatment Protocol Filename: | N A |
Sample Preparation:
| Sampleprep ID: | SP002151 |
| Sampleprep Summary: | Untargeted lipidomics samples were prepared by dissolving in dicholormethane/ methanol ( MeOH; 2:1). Untargeted metabolomics was done by centrifugation, samples were re-suspended with 60% ACN prior to analysis. FOR details please refer to publication Wang et al 2022. |
Combined analysis:
| Analysis ID | AN003362 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Vanquish UHPLC system |
| Column | Accucore C30 (150 x 2.1mm,2.6um) |
| MS Type | ESI |
| MS instrument type | Single quadrupole |
| MS instrument name | Thermo Q Exactive HF hybrid Orbitrap |
| Ion Mode | UNSPECIFIED |
| Units | Normalized ion intensity |
Chromatography:
| Chromatography ID: | CH002488 |
| Chromatography Summary: | Chromatographic separation was performed on a Vanquish UHPLC system with an Accucore C30, 2.6 μm column (2.1 mm id × 150mm) coupled to a Q Exactive™ Hybrid Quadrupole-Orbitrap High Resolution Mass Spectrometer (Thermo Fisher Scientific, San Jose, CA) and generated data was processed using LipidSearch™ software version 4.1 (Thermo Scientific), |
| Methods Filename: | Genenral_method_for_Untargeted_Metabolomics_Mar2020.docx |
| Instrument Name: | Vanquish UHPLC system |
| Column Name: | Accucore C30 (150 x 2.1mm,2.6um) |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS003131 |
| Analysis ID: | AN003362 |
| Instrument Name: | Thermo Q Exactive HF hybrid Orbitrap |
| Instrument Type: | Single quadrupole |
| MS Type: | ESI |
| MS Comments: | Please refer to publication Wang et al 2022. |
| Ion Mode: | UNSPECIFIED |
